# LC Ventures

> LC Ventures is a VC fund in Shanghai backing Medical and Biotechnology. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 13
- Last investment: Dec 2022
- Lead investor: 31%
- Last updated: Aug 2026
- Website: http://www.lcventures.cn/

LC Ventures is a VC fund in Shanghai focused on Medical and Biotechnology. Leading Ventures is a professional fund focused on investing in the innovative drug industry.

## Contacts

5 contacts available for LC Ventures. Shizune tracks 2 team members at LC Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lc-ventures-de51?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 6 | 46% |
| Biotechnology | 6 | 46% |
| Health Care | 5 | 38% |
| Pharmaceutical | 5 | 38% |
| Oncology | 1 | 8% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 54% |
| Series A | 3 | 23% |
| Seed | 2 | 15% |
| Venture - Series Unknown | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Leo Sun | Managing Partner | 1 | — |
| Sun Hangcheng | Partner | 3 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yuyao Biotech | Yuyao Bio is an innovative drug research and development company. | $13M | Seed | Dec 30, 2022 |  |
| LaNova Medicines | LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs. |  | Series B | Jun 28, 2022 |  |
| Haixin zhihui | Haixin zhihui is an artificial intelligence company. They offer intelligent diagnosis, and treatment systems for tumor diseases have been developed. They provide patients with precise treatment recommendations and assist patients in treatment planning and full disease management. |  | Series B | May 25, 2022 |  |
| Qinhao Pharmaceutical | Qinhao Pharmaceutical is harmaceutical enterprises with a gathering of humanities and innovation. | $15.7M | Series B | Feb 14, 2022 |  |
| Ractigen Therapeutics | Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation(RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need. | $30M | Series A | Jan 27, 2022 |  |
| Personal Oncology | Personal Oncology specializes in the diagnosis and treatment of tumors. It has developed a PDTX technology (FASTPDTX) that has reached the clinical use level. | $31.6M | Series B | Jan 21, 2022 |  |
| Chineo | Chineo is a CAR-T immune cell therapy service provider. | $90M | Series B | Oct 01, 2021 |  |
| Joyo Pharma | Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases. | $46.2M | Series B | Jul 28, 2021 |  |
| Immunophage Biotech | Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders. | $31.1M | Series A | May 11, 2021 |  |
| Stemirna | Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. |  | Series B | Sep 01, 2020 |  |

10 of 13 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [SDIC Venture Capital](https://shizune.co/investors/profile/sdic-venture-capital) — VC Fund, 2 deals together
- Shanghai Junshi Biosciences — VC Fund, 2 deals together
- [Beijing Jianxing Yiliao Jiankang Chanye Guquan Touzi Jijin](https://shizune.co/investors/profile/beijing-jianxing-yiliao-jiankang-chanye-guquan-touzi-jijin) — VC Fund, 1 deal together
- [China Singapore Suzhou Industrial Park Ventures](https://shizune.co/investors/profile/china-singapore-suzhou-industrial-park-ventures-co) — VC Fund, 1 deal together
- [Eisai](https://shizune.co/investors/profile/eisai-co) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does LC Ventures invest in?

LC Ventures invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LC Ventures?

Public channels for LC Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LC Ventures?

The team at LC Ventures includes Leo Sun (Managing Partner) and Sun Hangcheng (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co